Alternative Antimicrobial Strategies in Burns

Overview¶

Burn wound infection remains a leading cause of morbidity and mortality, and the rise of multidrug-resistant organisms has made conventional management progressively harder ^[1]. With long-term, widespread antibiotic use, bacterial drug resistance has become a major problem in burn infection treatment ^[3], and the relentless increase in microbial resistance has prompted a renewed search for approaches to prevent and combat burn infection beyond the standard antibiotic and silver-based armamentarium ^[4]. This page surveys those alternative strategies as a group: bacteriophage therapy, medical honey, probiotics, immunomodulation, antimicrobial peptides, nanoparticle and metal-based antimicrobials, and plant-derived agents.

These strategies sit at very different stages of evidence. Medical honey has been tested in human comparative trials and pooled in meta-analyses; bacteriophages have reached a multicenter randomized trial; the remaining modalities are mostly supported by animal models and in-vitro work. A 2024 review framed the situation as either an end or a new beginning for burn-infection management, cataloguing both new antibiotics and non-antibiotic therapies including bacteriophages and nanoparticles, and arguing that alternatives such as probiotics deserve further exploration ^[1]. The honest reading of this literature is that it is an active, largely investigational field rather than a settled set of clinical tools.

Pathophysiology and rationale¶

Two forces motivate alternative antimicrobials in burns: resistant pathogens and a compromised host. On the pathogen side, multidrug resistance is an intractable challenge in burn care ^[2], and infection by multiple-drug-resistant bacteria adds further complexity to the problem ^[11]. On the host side, severe burns cause immunosuppression, and the eschar itself remains an ideal culture medium for microbial growth ^[5].

The burn wound also has a specific innate-immune deficit that several strategies target directly. Reduced antimicrobial peptide expression has been documented in human burn wounds ^[37], human beta-defensin is absent in burn blister fluid ^[38], and decreased antimicrobial peptide production in tissue surrounding burn sites has been described in severely burned patients ^[8]. Mechanistically, lineage-negative CD34-positive cells that appear after severe burn injury inhibit antimicrobial peptide production by epidermal keratinocytes ^[39], and alterations in defensins may underlie the immune-deficiency pattern that facilitates infection and subsequent sepsis ^[7]. This host-defense gap is the rationale for both supplying exogenous antimicrobial peptides and restoring endogenous ones: in a mouse model, glycyrrhizin improved beta-defensin production in tissue around the burn and improved resistance to Pseudomonas aeruginosa wound infection ^[8]. Early experimental work showed the same logic for phagocytosis, where thermal injury profoundly depressed phagocytic activity in rats and immunostimulation restored it toward healthy levels ^[6].

Bacteriophage therapy¶

Bacteriophages are viruses that infect and lyse bacteria, and for multidrug-resistant burn pathogens they have become a focus of attention ^[3]. The mechanistic case is strongest for Pseudomonas: phages have been proposed for post-burn infection by the ubiquitous opportunistic Pseudomonas species notorious for antibiotic resistance ^[11], and the landmark preclinical study in this canon used a liposome-loaded phage cocktail against Klebsiella pneumoniae burn wound infection, where the liposomal preparation increased phage retention time in vivo, reduced bacterial load in blood and organs, and protected all test animals from death even when therapy was delayed 24 hours ^[9]. Other murine work showed a single bacteriophage preparation could protect against fatal K. pneumoniae burn infection by routes including subcutaneous and intraperitoneal administration ^[12], and that topical phage rescued mice from K. pneumoniae burn infection ^[13].

Two refinements appear repeatedly. First, phages act on biofilm as well as planktonic bacteria: phage PhiPan70 reduced P. aeruginosa populations in both planktonic cells and biofilms in a burn mouse model ^[14]. Second, combining phages with antibiotics improves killing; in vitro, a two-phage-plus-one-antibiotic combination achieved the highest killing efficiency against a P. aeruginosa strain from a burn patient, supporting phage-antibiotic cocktails at sub-MIC levels against multidrug-resistant Pseudomonas ^[15]. More recent ex-vivo work in porcine and human skin models found a single phage treatment reduced Staphylococcus aureus load, prophylaxis increased efficacy, and phage outperformed the antibiotic control ^[16]. Phage-derived lysins are a related avenue: the lysin LysP53 decolonized Acinetobacter baumannii in a mouse burn model more effectively than minocycline ^[17].

The decisive clinical datum is the PhagoBurn trial, a randomized, controlled, double-blind phase 1/2 study of a phage cocktail against P. aeruginosa-infected burn wounds. It did not succeed. The trial was stopped because of insufficient efficacy of the cocktail (PP1131) ^[10], the primary endpoint was reached more slowly in the phage group than in standard care (median 144 h versus 47 h; hazard ratio 0.29) ^[10], and the phage group decreased bacterial burden at a slower pace than standard of care at the very low concentrations actually delivered ^[10]. The likely explanation is dosing: the phage titre decreased after manufacturing, so participants received a far lower phage concentration than intended ^[10], and bacteria from participants who failed treatment were resistant to the low phage doses ^[10]. Adverse events were fewer in the phage group than in standard care ^[10]. PhagoBurn is therefore best read as a failure of formulation and dose rather than a disproof of the concept, but it stands as the most rigorous clinical test to date and it was negative.

Medical honey¶

Medical honey is the most clinically studied alternative antimicrobial in burns. Honey with proven antibacterial activity has been identified as a potential treatment for burns infected or at risk of infection with P. aeruginosa ^[26], and laboratory and clinical studies describe it as an effective broad-spectrum antibacterial agent. A series of single-center comparative trials reported striking results: in 52 honey-treated patients, 91% of wounds were rendered sterile within 7 days versus 7% infection control with silver sulfadiazine ^[18], and 87% of honey-treated wounds healed within 15 days versus 10% of controls ^[18]. Subsequent trials by the same group found honey healed burns faster than amniotic membrane (mean 9.4 versus 17.5 days) ^[19] and faster than boiled potato peel, with 100% healed by 15 days versus 50% ^[20].

Pooled analyses point in the same direction while flagging the weakness of the underlying trials. A meta-analysis found a random-effects pooled odds ratio of 6.7 favoring honey ^[22], and a Cochrane review concluded that in partial-thickness burns honey might reduce time to healing compared with some conventional dressings (weighted mean difference -4.68 days) ^[23]. An earlier Cochrane analysis reported the same partial-thickness finding ^[29], a 2008 systematic review noted a number-needed-to-treat of 2.6 to heal one additional burn at 7 days ^[21], and a comparison of honey against silver concluded honey carried more antibacterial activity without silver's skin toxicity ^[25]. A separate review found honey reduced mean healing time relative to non-antibacterial treatments ^[24], and a formulated 20% active-honey ointment showed promising clinical control of burn-wound infection as a low-cost preparation ^[58].

The limitations are explicit in the same literature and belong in any honest appraisal. Many trials originated from a single center, which affects replicability ^[29]; study quality was generally low, with most trials at high or unclear risk of bias ^[23]; and there is considerable uncertainty about the replicability and applicability of the evidence ^[23]. Crucially, when honey was compared against the modern standard of care rather than against passive dressings, it lost: early tangential excision and skin grafting was clearly superior to expectant honey treatment in moderate burns ^[27], and one meta-analysis found that, compared with early excision and grafting, honey delayed healing in partial- and full-thickness burns by roughly 13.6 days ^[23]. Honey may also fail to prevent deep bacterial complications such as chondritis ^[28].

Probiotics¶

Probiotics are pursued in burns mainly to defend the gut barrier and limit translocation, the route by which enteric organisms seed systemic infection. In rat scald models, probiotic supplementation reduced bacterial and endotoxin translocation and supported intestinal barrier function ^[35], and probiotic supplementation reduced bacterial translocation and intestinal mucosal atrophy in thermally injured rats, as did arginine- and glutamine-enriched enteral solutions ^[36]. In a more aggressive model, local probiotic therapy reduced mortality from over 90% to under 10% in Pseudomonas-infected animals and suppressed septicemic spread of the pathogen to remote organs ^[31].

Clinical translation is cautious. Probiotic use after burns has been limited by concern over the potential for bacterial translocation and infection risk in an immunocompromised population ^[30]. A small randomized trial addressed exactly this: subjects received probiotic or placebo twice daily, the study documented safety with flatulence the main difference, and time to wound healing was shorter with probiotics although length of stay was not ^[30]. An earlier clinical report suggested Lactobacillus food additives may be beneficial in acute burns of 41 to 70% total body surface area ^[34]. Other work tempers expectations; a heat-killed Lactobacillus plantarum preparation altered neutrophil function but did not improve survival in murine burn injury ^[32], and screening models continue to search for strains that limit P. aeruginosa burn infection and improve survival ^[33].

Antimicrobial peptides¶

Antimicrobial peptides are naturally occurring cationic effectors of innate immunity, and the documented deficit of these peptides in burned skin makes both replacement and induction attractive ^[37][7]. Because beta-defensins have potent bactericidal activity against the organisms commonly responsible for burn wound infection ^[37], supplying them exogenously is one approach: a mixture of an antimicrobial peptide and fibrin glue significantly reduced bacteria in infected partial-thickness burns in vivo compared with controls ^[41], the synthetic peptide D2A21 improved burn wound infection and survival in an animal model ^[42], and the novel peptide PXL150 showed efficacy with a favorable safety profile in repeated administration in animals ^[43]. Restoring or delivering endogenous peptides is another: transient cutaneous adenoviral delivery of the host-defense peptide hCAP-18/LL-37 was more effective than synthetic peptide administration and showed marked bacterial inhibition in a burn model ^[40]. All of this work is preclinical; antimicrobial peptides remain an experimental class in burns without controlled human efficacy data in this canon.

Nanoparticle and metal-based antimicrobials¶

Nanoparticle and metal-based antimicrobials are the largest body of work in this field, dominated by silver nanoparticle dressings. Reviews summarize the antibacterial mechanisms of silver nanoparticles and their application in burns ^[45], and a systematic review found nanoparticle-based dressings increased healing speed with good antibacterial capacity and low cytotoxicity ^[49]. Preclinical and early clinical reports are favorable: a silver nanoparticle dressing was comparable to 1% silver sulfadiazine for wound colonization and was judged usable on second-degree burns to lower infection risk and accelerate healing ^[44], and engineered systems such as a gelatin/silver-nanoparticle cryogel combined antibacterial and antibiofilm activity for Pseudomonas-infected burn healing ^[48]. Beyond silver, zinc-based agents are emerging; zinc peroxide nanoparticles showed antimicrobial activity against multidrug-resistant P. aeruginosa from burn wounds ^[2], and a graphene-supported silver nanoparticle system was studied for antimicrobial performance and burn healing ^[47].

The one controlled human datum in this canon is small and population-specific: a retrospective study of a touchless zinc oxide spray for pediatric perineal burns reported faster healing than silver sulfadiazine (12.2 versus 16.9 days) with no infections observed, described as the first human study of zinc oxide for burn management ^[46]. That same report also captured the field's central safety caveat, noting that silver nanoparticles could negatively affect healing time through toxicity to keratinocytes and fibroblasts at higher concentrations ^[46]. The toxicity of silver nanoparticles is concentration- and ion-release-dependent ^[47], which is why much of the engineering effort targets controlled, lower-dose delivery.

Plant-derived and immunomodulatory agents¶

A range of plant-derived agents and host-directed immunomodulators round out the field, all at preclinical or descriptive stages. Among natural products, standardized propolis showed concentration-dependent antibacterial activity and improved in-vivo burn healing without skin irritation, alongside downregulation of TLR4, IL-6, and TNF-alpha ^[50], and beta-glucan protected against burn-induced oxidative organ damage in rats while also carrying antioxidant properties ^[51]. Reviews note tannins, essential oils, and other natural-product antimicrobials under study for burn infection ^[59], and an update on topical antimicrobials describes the use of therapeutic microorganisms such as phages and probiotic bacteria as an active area of innovation ^[59].

Immunomodulation pursues the complementary goal of correcting post-burn immune dysfunction rather than killing bacteria directly. Glucan phosphate attenuated burn-induced inflammation and improved resistance to P. aeruginosa burn wound infection in mice ^[52]. The TLR4 agonist monophosphoryl lipid A, already used as a human vaccine adjuvant, augmented innate host resistance to systemic bacterial infection ^[53] and attenuated multiorgan dysfunction during post-burn P. aeruginosa pneumonia in sheep ^[54]. In an early clinical report, the thymic peptide Thymalin added to multimodality therapy contributed to normalization of immunological parameters in burn patients ^[55], and classic animal work showed immunomodulating drugs improved resistance to septic challenge after burn ^[56]. Immunonutrition occupies a related niche; a Cochrane review of glutamine and other immunonutrition agents found a reduction in length of hospital stay but no demonstrated effect on burn wound infection, and concluded larger studies are needed ^[57].

Complications and Safety¶

The safety signals across these strategies are modality-specific and incompletely characterized. For silver nanoparticles, the dominant concern is cytotoxicity to host cells, with reports that higher concentrations can negatively affect healing through toxic effects on keratinocytes and fibroblasts ^[46] and that silver-ion release governs that toxicity ^[47]; engineered systems are explicitly designed to keep cytotoxicity low ^[48]. For probiotics, the historical concern is translocation and infection in an immunocompromised host, though the available small RCT documented safety with flatulence as the main adverse effect ^[30]. For phages, the PhagoBurn trial reported fewer adverse events in the phage group than in standard care ^[10], and several peptide candidates showed favorable preclinical safety profiles ^[43]. Honey carries the practical caveat that it may not prevent deep bacterial complications such as chondritis, so it is not a substitute for definitive wound management in deep injuries ^[28].

Outcomes¶

Outcome data thin out quickly once the question moves from surrogate measures to definitive endpoints. The strongest pooled outcome is honey's effect on time to healing in partial-thickness burns, where meta-analyses report a reduction of roughly 4 to 5 days against some conventional dressings ^[23][24] but a delay relative to early excision and grafting ^[23]. For probiotics, the small clinical RCT found shorter time to wound healing without a change in length of stay ^[30], and immunonutrition reduced hospital stay without affecting infection rates ^[57]. Preclinical survival benefits are reported for liposomal phage cocktails ^[9], local probiotics in Pseudomonas-infected animals ^[31], and glucan phosphate ^[52], but these have not been reproduced in controlled human trials. The PhagoBurn result is the cautionary counterpoint: the single rigorous clinical efficacy trial in this group was negative on its primary endpoint ^[10].

Special Considerations¶

Pediatric data are sparse and confined to single studies. The clearest example is the zinc oxide preparation that healed pediatric perineal burns faster than silver sulfadiazine in a retrospective comparison ^[46]. The broader pattern across special populations is absence of evidence rather than evidence of safety: most trials enroll adults or use animal models, and extrapolation to children, the elderly, or resource-limited settings is not supported by controlled data in this canon. In resource-limited care, several of these agents, including honey and certain plant-derived products, are attractive for their low cost and availability ^[18], but that practical appeal does not substitute for efficacy data against the modern standard of care.

Controversies and Evidence Gaps¶

The defining tension in this field is between mechanistic promise and clinical proof. Bacteriophages illustrate it sharply: a strong preclinical record and a clear rationale against multidrug-resistant Pseudomonas ^[11][9], yet the one randomized clinical trial was stopped for insufficient efficacy, undermined by a manufacturing-related drop in phage titre and consequent under-dosing ^[10]. Whether PhagoBurn indicts the concept or only its formulation is genuinely unsettled, and it is the central open question for phage therapy in burns.

Honey faces a different problem: a relatively large but methodologically weak evidence base. Many trials came from a single center ^[29], study quality was generally low with most trials at high or unclear risk of bias ^[23], and the favorable comparisons are largely against passive dressings rather than against the modern standard, against which honey delays healing ^[23][27]. The dosage, safety, and formulation of medical honey also remain incompletely standardized.

For the remaining modalities, the gap is simply a near-total absence of controlled human data. Antimicrobial peptides, immunomodulators, and most nanoparticle systems rest on animal and in-vitro work ^[40][52][49]; probiotics carry an unresolved translocation-safety question despite encouraging early data ^[30]; and silver-nanoparticle cytotoxicity remains a real constraint on dosing ^[46]. Substantial experimental progress has been made in correcting post-burn immune defects, but clinical application is still limited ^[56]. The reasonable summary is that these are emerging, largely investigational strategies: a fertile area of innovation ^[59], not a body of established clinical practice.

References¶

[1] Hagiga A, Dheansa B. "Multi-resistant organisms in burn patients: an end or a new beginning." Burns : journal of the International Society for Burn Injuries 2024. PMID: 38472000. ↩

[2] Ali SS, et al. "Synthesized zinc peroxide nanoparticles (ZnO2-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds." International journal of nanomedicine 2017. PMID: 28860766. ↩

[3] Peng YZ, Huang GT. "[Phage therapy for bacterial infection of burn]." Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2016. PMID: 27647065. ↩

[4] Dai T, et al. "Topical antimicrobials for burn wound infections." Recent patents on anti-infective drug discovery 2010. PMID: 20429870. ↩

[5] Poindexter BJ, et al. "Localization of antimicrobial peptides in normal and burned skin." Burns : journal of the International Society for Burn Injuries 2006. PMID: 16621313. ↩

[6] Jacques L, et al. "[Variations in the phagocytic potency of circulating leukocytes from rats which received a thermal injury. Effects of an immunostimulation with Corynebacterium granulosum (author's transl)]." Pathologie-biologie 1978. PMID: 370744. ↩

[7] Bhat S, Milner S. "Antimicrobial peptides in burns and wounds." Current protein & peptide science 2007. PMID: 17979765. ↩

[8] Yoshida T, et al. "Pivotal advance: glycyrrhizin restores the impaired production of beta-defensins in tissues surrounding the burn area and improves the resistance of burn mice to Pseudomonas aeruginosa wound infection." Journal of leukocyte biology 2010. PMID: 19843573. ↩

[9] Chadha P, et al. "Liposome loaded phage cocktail: Enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections." Burns : journal of the International Society for Burn Injuries 2017. PMID: 28502784. ↩

[10] Jault P, et al. "Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial." The Lancet. Infectious diseases 2019. PMID: 30292481. ↩

[11] Ahmad SI. "Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics." Medical hypotheses 2002. PMID: 12027527. ↩

[12] Malik R, Chhibber S. "Protection with bacteriophage KØ1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice." Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2009. PMID: 19597645. ↩

[13] Kumari S, et al. "Topical treatment of Klebsiella pneumoniae B5055 induced burn wound infection in mice using natural products." Journal of infection in developing countries 2010. PMID: 20601788. ↩

[14] Holguín AV, et al. "Phage ΦPan70, a Putative Temperate Phage, Controls Pseudomonas aeruginosa in Planktonic, Biofilm and Burn Mouse Model Assays." Viruses 2015. PMID: 26274971. ↩

[15] Aghaee BL, et al. "Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics." Viruses 2021. PMID: 33670028. ↩

[16] Molendijk MM, et al. "Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model." Antimicrobial agents and chemotherapy 2024. PMID: 39136463. ↩

[17] Li C, et al. "Intrinsic Antimicrobial Peptide Facilitates a New Broad-Spectrum Lysin LysP53 to Kill Acinetobacter baumannii In Vitro and in a Mouse Burn Infection Model." ACS infectious diseases 2021. PMID: 34788533. ↩

[18] Subrahmanyam M. "Topical application of honey in treatment of burns." The British journal of surgery 1991. PMID: 2032114. ↩

[19] Subrahmanyam M. "Honey-impregnated gauze versus amniotic membrane in the treatment of burns." Burns : journal of the International Society for Burn Injuries 1994. PMID: 7945822. ↩

[20] Subrahmanyam M. "Honey dressing versus boiled potato peel in the treatment of burns: a prospective randomized study." Burns : journal of the International Society for Burn Injuries 1996. PMID: 8884013. ↩

[21] Moore OA, et al. "Systematic review of the use of honey as a wound dressing." BMC complementary and alternative medicine 2001. PMID: 11405898. ↩

[22] Wijesinghe M, et al. "Honey in the treatment of burns: a systematic review and meta-analysis of its efficacy." The New Zealand medical journal 2009. PMID: 19648986. ↩

[23] Jull AB, et al. "Honey as a topical treatment for wounds." The Cochrane database of systematic reviews 2013. PMID: 23450557. ↩

[24] Norman G, et al. "Antiseptics for burns." The Cochrane database of systematic reviews 2017. PMID: 28700086. ↩

[25] Lindberg T, et al. "A systematic review and meta-analysis of dressings used for wound healing: the efficiency of honey compared to silver on burns." Contemporary nurse 2015. PMID: 27027667. ↩

[26] Cooper RA, et al. "The efficacy of honey in inhibiting strains of Pseudomonas aeruginosa from infected burns." The Journal of burn care & rehabilitation 2002. PMID: 12432313. ↩

[27] Subrahmanyam M. "Early tangential excision and skin grafting of moderate burns is superior to honey dressing: a prospective randomised trial." Burns : journal of the International Society for Burn Injuries 1999. PMID: 10630854. ↩

[28] Hashemi B, et al. "Comparison between topical honey and mafenide acetate in treatment of auricular burn." American journal of otolaryngology 2011. PMID: 20015812. ↩

[29] Jull AB, et al. "Honey as a topical treatment for wounds." The Cochrane database of systematic reviews 2008. PMID: 18843679. ↩

[30] Mayes T, et al. "Clinical safety and efficacy of probiotic administration following burn injury." Journal of burn care & research : official publication of the American Burn Association 2015. PMID: 25559730. ↩

[31] Argenta A, et al. "Local Application of Probiotic Bacteria Prophylaxes against Sepsis and Death Resulting from Burn Wound Infection." PloS one 2016. PMID: 27780258. ↩

[32] Schuermann LE, et al. "Heat-killed probiotic Lactobacillus plantarum affects the function of neutrophils but does not improve survival in murine burn injury." Burns : journal of the International Society for Burn Injuries 2023. PMID: 35850881. ↩

[33] Maslova E, et al. "Using the Galleria mellonella burn wound and infection model to identify and characterize potential wound probiotics." Microbiology (Reading, England) 2023. PMID: 37350463. ↩

[34] Koren L, et al. "The effect of Lactobacillus bacteria supplement on sepsis and its complications in patients with acute burns." Burns : journal of the International Society for Burn Injuries 2007. PMID: 17482370. ↩

[35] Wang ZT, et al. "[The protective effect of supplementation of probiotics combined with riboflavin on the intestinal barrier of the rats after scald injury]." Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2004. PMID: 15447817. ↩

[36] Gun F, et al. "Effect of probiotic supplementation on bacterial translocation in thermal injury." Surgery today 2005. PMID: 16133671. ↩

[37] Milner SM, Ortega MR. "Reduced antimicrobial peptide expression in human burn wounds." Burns : journal of the International Society for Burn Injuries 1999. PMID: 10439149. ↩

[38] Ortega MR, et al. "Human beta defensin is absent in burn blister fluid." Burns : journal of the International Society for Burn Injuries 2000. PMID: 11024605. ↩

[39] Yoshida S, et al. "Lineage -CD34+CD31+ cells that appear in association with severe burn injury are inhibitory on the production of antimicrobial peptides by epidermal keratinocytes." PloS one 2014. PMID: 24498256. ↩

[40] Jacobsen F, et al. "Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections." Gene therapy 2005. PMID: 15973442. ↩

[41] Lahoda LU, et al. "[A mixture of antimicrobial peptides and fibrin glue in treatment of partial-thickness burn wounds]." Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2006. PMID: 16208508. ↩

[42] Chalekson CP, et al. "Improvement in burn wound infection and survival with antimicrobial peptide D2A21 (Demegel)." Plastic and reconstructive surgery 2002. PMID: 11964988. ↩

[43] Björn C, et al. "Efficacy and safety profile of the novel antimicrobial peptide PXL150 in a mouse model of infected burn wounds." International journal of antimicrobial agents 2015. PMID: 25649371. ↩

[44] Chen J, et al. "[Effect of silver nanoparticle dressing on second degree burn wound]." Zhonghua wai ke za zhi [Chinese journal of surgery] 2006. PMID: 16620649. ↩

[45] Liu MZ, et al. "[Advances in the research of antibacterial function of silver nanoparticle and its application in burn treatment]." Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns 2017. PMID: 28219144. ↩

[46] Diab WC, et al. "A Retrospective Study of Touchless Spray for Pediatric Perineal Burns Treatment." Journal of burn care & research : official publication of the American Burn Association 2022. PMID: 34309678. ↩

[47] Zhou Y, et al. "Biomedical Potential of Ultrafine Ag/AgCl Nanoparticles Coated on Graphene with Special Reference to Antimicrobial Performances and Burn Wound Healing." ACS applied materials & interfaces 2016. PMID: 27064187. ↩

[48] Huang Y, et al. "Biodegradable gelatin/silver nanoparticle composite cryogel with excellent antibacterial and antibiofilm activity and hemostasis for Pseudomonas aeruginosa-infected burn wound healing." Journal of colloid and interface science 2022. PMID: 34774324. ↩

[49] Silva MMP, et al. "The use of nanoparticles in wound treatment: a systematic review." Revista da Escola de Enfermagem da U S P 2018. PMID: 29319738. ↩

[50] El-Kersh DM, et al. "In vitro and in vivo burn healing study of standardized propolis: Unveiling its antibacterial, antioxidant and anti-inflammatory actions in relation to its phytochemical profiling." PloS one 2024. PMID: 38743731. ↩

[51] Toklu HZ, et al. "beta-glucan protects against burn-induced oxidative organ damage in rats." International immunopharmacology 2006. PMID: 16399620. ↩

[52] Lyuksutova OI, et al. "Glucan phosphate treatment attenuates burn-induced inflammation and improves resistance to Pseudomonas aeruginosa burn wound infection." Shock (Augusta, Ga.) 2005. PMID: 15718919. ↩

[53] Romero CD, et al. "The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection." Infection and immunity 2011. PMID: 21646453. ↩

[54] Fukuda S, et al. "Monophosphoryl Lipid a Attenuates Multiorgan Dysfunction During Post-Burn Pseudomonas Aeruginosa Pneumonia in Sheep." Shock (Augusta, Ga.) 2020. PMID: 31045990. ↩

[55] Shkrob LO, et al. "[Correction of immunologic disorders in patients with burns]." Khirurgiia 1990. PMID: 2335880. ↩

[56] Zapata-Sirvent RL, et al. "Postburn immunosuppression in an animal model. IV. Improved resistance to septic challenge with immunomodulating drugs." Surgery 1986. PMID: 2934837. ↩

[57] Tan HB, et al. "Immunonutrition as an adjuvant therapy for burns." The Cochrane database of systematic reviews 2014. PMID: 25536183. ↩

[58] Tasleem S, et al. "Efficacy of newly formulated ointment containing 20% active antimicrobial honey in treatment of burn wound infections." Journal of Ayub Medical College, Abbottabad : JAMC 2013. PMID: 25098080. ↩

[59] Sevgi M, et al. "Topical antimicrobials for burn infections - an update." Recent patents on anti-infective drug discovery 2013. PMID: 24215506. ↩